What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?

Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...